CYP2C19 Metabolizer Status Predicts Sertraline and Escitalopram Pharmacokinetics in Children and Adolescents

被引：0
|
作者：
Poweleit, Ethan [1 ]
Vaughn, Samuel [1 ]
Desta, Zeruesenay [1 ]
Ramsey, Laura [1 ]
Strawn, Jeffrey [1 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2021年 / 46卷 / SUPPL 1期
关键词：
SSRI; Pharmacokinetics; Precision Medicine for Mood and Anxiety Disorders; Adolescent Anxiety;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P159
引用
收藏
页码：154 / 154
页数：1
相关论文
共 50 条
  • [1] CYP2C19 METABOLIZER STATUS PREDICTS ESCITALOPRAM PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Vaughn, Sam
    Poweleit, Ethan
    Desta, Zeruesenay
    Strawn, Jeffrey
    Ramsey, Laura
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 60 (10): : S215 - S215
  • [2] CYP2C19 METABOLIZER PHENOTYPE PREDICTS SERTRALINE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Poweleit, Ethan
    Vaughn, Samuel
    Desta, Zeruesenay
    Strawn, Jeffrey
    Ramsey, Laura
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 51 : E132 - E132
  • [3] CYP2C19 METABOLIZER STATUS PREDICTS ESCITALOPRAM PHARMACOKINETICS IN ADOLESCENTS WITH GENERALIZED ANXIETY DISORDER
    Tulisiak, Anne K.
    Poweleit, Ethan
    Ramsey, Laura A.
    Mills, Jeffrey A.
    Varney, Sara T.
    Mossman, Sarah
    Schroeder, Heidi K.
    Delbello, Melissa P.
    Strawn, Jeffrey Robert
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2019, 58 (10): : S247 - S247
  • [4] CYP2C19 METABOLIZER PHENOTYPE INFLUENCES SERTRALINE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS.
    Vaughn, S.
    Poweleit, E.
    Desta, Z.
    Strawn, J.
    Ramsey, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S54 - S54
  • [5] PHARMACOGENETIC INFLUENCE OF CYP2C19 VARIATION ON ESCITALOPRAM PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS.
    Poweleit, E.
    Vaughn, S.
    Desta, Z.
    Strawn, J.
    Ramsey, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S41 - S41
  • [6] Sertraline dosing trends in children and adolescents stratified by CYP2C19 genotype
    Brown, Jacob T.
    Gregornik, David B.
    Jorgenson, Alissa
    Watson, Dave
    Roiko, Samuel A.
    Bishop, Jeffrey R.
    [J]. PHARMACOGENOMICS, 2022, 23 (04) : 247 - 253
  • [7] Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
    Wang, JH
    Liu, ZQ
    Wang, W
    Chen, XP
    Shu, Y
    He, N
    Zhou, HH
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (01) : 42 - 47
  • [8] Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders
    Aldrich, Stacey L.
    Poweleit, Ethan A.
    Prows, Cynthia A.
    Martin, Lisa J.
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [9] A POPULATION PHARMACOKINETIC ANALYSIS OF ESCITALOPRAM AND THE EFFECT OF CYP2C19 ON CLEARANCE IN CHILDREN AND ADOLESCENTS
    Poweleit, E.
    Mizuno, T.
    Taylor, Z.
    Vaughn, S.
    Desta, Z.
    Strawn, J.
    Ramsey, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S25 - S25
  • [10] CYP2C19 METABOLIZER STATUS IS ASSOCIATED WITH ESCITALOPRAM/CITALOPRAM TOLERABILITY AND RESPONSE IN YOUTH WITH ANXIETY AND DEPRESSIVE DISORDERS.
    Aldrich, S. L.
    Poweleit, E.
    Prows, C. A.
    Martin, L. J.
    Strawn, J. R.
    Ramsey, L. B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S69 - S69
12345